בוסטריקס פוליו

Land: Israel

Språk: hebraisk

Kilde: Ministry of Health

Aktiv ingrediens:

DIPHTHERIA TOXOID; FILAMENTOUS HAEMAGGLUTININ (FHA); INACTIVATED POLIO VIRUS (IPV) TYPE 1; INACTIVATED POLIO VIRUS (IPV) TYPE 2; INACTIVATED POLIO VIRUS (IPV) TYPE 3; PERTACTIN (PRN OR 69 KDA OMP); PERTUSSIS TOXOID VACCINE; TETANUS TOXOID

Tilgjengelig fra:

GLAXO SMITH KLINE (ISRAEL) LTD

ATC-kode:

J07CA

Legemiddelform:

תרחיף להזרקה

Sammensetning:

PERTACTIN (PRN OR 69 KDA OMP) 2.5 MCG / 0.5 ML; DIPHTHERIA TOXOID NLT 2 IU / 0.5 ML; TETANUS TOXOID NLT 20 IU / 0.5 ML; FILAMENTOUS HAEMAGGLUTININ (FHA) 8 MCG / 0.5 ML; PERTUSSIS TOXOID VACCINE 8 MCG / 0.5 ML; INACTIVATED POLIO VIRUS (IPV) TYPE 3 32 DU / 0.5 ML; INACTIVATED POLIO VIRUS (IPV) TYPE 1 40 DU / 0.5 ML; INACTIVATED POLIO VIRUS (IPV) TYPE 2 8 DU / 0.5 ML

Administreringsrute:

תוך-שרירי

Resept typen:

מרשם נדרש

Produsert av:

GLAXO SMITH KLINE BIOLOGICALS S.A

Terapeutisk gruppe:

BACTERIAL AND VIRAL VACCINES, COMBINED

Indikasjoner:

For Booster vaccination against diphtheria, tetanus and pertusis and poliomyelitis of individuals from the age of four years onwards. Boostrix polio is not intended for primary immunisation. The administration of Boostrix Polio should be based on official recommendations.

Autorisasjon dato:

2022-06-30

Informasjon til brukeren

1986 -
ʥ
"
ʮʹʺʤ (
ʭʩʸʩʹʫʺ
)
ʭʩʧʷʥʸʤ
ʺʥʰʷʺ
ʩʴʬ
ʯʫʸʶʬ
ʯʥʬʲ
ʤʴʥʸʺʤ
ʺʷʥʥʹʮ
ʬʲ
ʩʴ
ʭʹʸʮ
ʠʴʥʸ
ʣʡʬʡ
ʱʷʩʸʨʱʥʡ
ʥʩʬʥʴ
ʳʩʧʸʺ
ʤʷʸʦʤʬ
ʷʸʦʮʡ
ʯʫʥʮ
ʹʥʮʩʹʬ
ʬʫ
ʤʰʮ
)
0.5
ʮ
"
ʬ
(
ʤʬʩʫʮ
:
diphtheria toxoid ‒ NLT 2 IU
)
ʣʩʠʥʱʷʥʨ
ʤʩʸʺʴʩʣ
(
tetanus toxoid ‒ NLT 20 IU
)
ʣʩʠʥʱʷʥʨ
ʱʥʰʨʨ
(
pertussis toxoid (PT) ‒ 8 mcg
)
ʣʩʠʥʱʷʥʨ
ʺʬʲʹ
(
filamentous hemagglutinin (FHA) ‒ 8 mcg
pertactin (PRN, or 69kDa OMP) ‒ 2.5 mcg
inactivated Polio Virus type 1 ‒ 40 DU
)
ʳʩʢʰ
ʥʩʬʥʴ
ʠʬ
ʬʩʲʴ
ʢʥʱʮ
1
(
inactivated Polio Virus type 2 ‒ 8 DU
)
ʳʩʢʰ
ʥʩʬʥʴ
ʠʬ
ʬʩʲʴ
ʢʥʱʮ
2
(
inactivated Polio Virus type 3 ‒ 32 DU
)
ʳʩʢʰ
ʥʩʬʥʴ
ʠʬ
ʬʩʲʴ
ʢʥʱʮ
3
(
ʺʮʩʹʸʬ
ʭʩʸʮʥʧʤ
ʩʺʬʡʤ
ʭʩʬʩʲʴ
ʭʩʩʰʢʸʬʠʥ
ʸʩʹʫʺʡ
,
ʤʠʸ
ʳʩʲʱ
2
‒
"
ʲʣʩʮ
ʡʥʹʧ
ʬʲ
ʷʬʧ
ʭʩʡʩʫʸʮʤʮ
ʬʹ
ʤʴʥʸʺʤ
"
ʳʩʲʱʥ
6
‒
"
ʲʣʩʮ
ʳʱʥʰ
."
ʠʸʷ
ʯʥʩʲʡ
ʺʠ
ʯʥʬʲʤ
ʣʲ
ʥʴʥʱ
ʭʸʨʡ
ʹʮʺʹʺ
ʤʴʥʸʺʡ
.
ʯʥʬʲ
ʤʦ
ʬʩʫʮ
ʲʣʩʮ
ʩʺʩʶʮʺ
ʬʲ
ʤʴʥʸʺʤ
.
ʭʠ
ʹʩ
ʪʬ
ʺʥʬʠʹ
ʺʥʴʱʥʰ
,
ʤʰʴ
ʬʠ
ʠʴʥʸʤ
ʥʠ
ʬʠ
ʧʷʥʸʤ
.
ʤʴʥʸʺ
ʥʦ
ʤʮʹʸʰ
ʪʸʥʡʲ
.
ʬʠ
ʸʩʡʲʺ
ʤʺʥʠ
ʭʩʸʧʠʬ
.
ʠʩʤ
ʤʬʥʬʲ
ʷʩʦʤʬ
ʭʤʬ
ʥʬʩʴʠ
ʭʠ
ʤʠʸʰ
ʪʬ
ʩʫ
ʭʡʶʮ
ʩʠʥʴʸʤ
ʤʮʥʣ
.
1
.
ʤʮʬ
ʺʣʲʥʩʮ
ʤʴʥʸʺʤ
?
ʬ
ʯʥʱʩʧ
ʳʧʣ
ʣʢʰʫ
ʤʩʸʺʴʩʣ
)
ʺʮʸʷ
(
,
ʱʥʰʨʨ
)
ʺʶʬʴ
(
,
ʺʬʲʹ
ʥʩʬʥʴʥ
ʬʹ
ʭʩʣʩʧʩ
ʬʧʤ
ʬʩʢʮ
ʹʥʬʹ
ʭʩʰʹ
.
ʯʺʮʤ
ʪʩʸʶ
ʱʱʡʺʤʬ
ʬʲ
ʺʥʶʬʮʤʤ
ʺʥʩʮʹʸʤ
.
ʤʶʥʡʷ
ʺʩʨʩʥʴʸʺ
:
ʭʩʰʥʱʩʧ
ʭʩʡʬʥʹʮ
ʭʩʩʷʣʩʩʧ
ʭʩʩʴʩʢʰʥ
(Bacterial and viral vaccines
combined)
ʣʶʩʫ
ʯʥʱʩʧʤ
ʣʡʥʲ
?
ʯʥʱʩʧʤ
ʣʡʥʲ
ʬʲ
ʩʣʩ
ʪʫ
ʠʥʤʹ
ʭʸʥʢ
ʳʥʢʬ
ʸʶʩʩʬ
ʤʰʢʤ
ʥʬʹʮ
)
ʭʩʰʣʢʥʰ
(
ʣʢʰʫ
ʺʥʬʧʮ
ʤʬʠ
)
ʤʩʸ